Últimas noticias sobre Schrodinger (NASDAQ:SDGR) Bolsa

Schrodinger

Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Schrodinger Inc

In a report released today, Scott Schoenhaus from KeyBanc maintained a Buy rating on Schrodinger (SDGR – Research Report), with a price target of $...

KeyBanc Keeps Their Buy Rating on Schrodinger (SDGR)

BMO Capital raised the firm's price target on Schrodinger (SDGR) to $28 from $25 and keeps an Outperform rating on the shares. The company reported...

Schrodinger price target raised to $28 from $25 at BMO Capital

Goldman Sachs raised the firm's price target on Schrodinger (SDGR) to $28 from $27 and keeps a Neutral rating on the shares. The company's Q3 resul...

Schrodinger price target raised to $28 from $27 at Goldman Sachs

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on SDGR stock, giving a Buy rating yesterday. Mani Foroohar has given hi...

Schrodinger's Strategic Collaborations and Financial Position Bolster Buy Rating Amid Market Confidence and Future Growth Potential

Schrodinger (SDGR) announced that it is broadening and accelerating its initiative to expand the company's computational platform to predict toxico...

Schrodinger gets additional funding to expand toxicology risk initiative

Schrödinger: Positive Signs Despite The Share Price Decline

Stocks with improving and deteriorating 'TechniGrade' by Piper Sandler

2024's 'Biggest loses' that could see reversal in 2025

2024's 'Biggest losers' that could see reversal in 2025

2024 Performance Review And Future Strategy

ABCL

ACCD

ALGM

AMGN

AMRK

AMRX

ANSS

APPF

ARQT

ARWR

AVDX

AVGO

AZTA

BMBL

BOWL

CBRL

CHGG

COHU

CRSP

CTKB

DECK

DIOD

ESTC

FIVE

FIVN

GILD

GNTX

HSIC

JNPR

KRMD

KRYS

KURA

LSCC

MKTX

NBHC

NRIX

NTLA

NVDA

OSCR

POWI

QDEL

ROKU

RSKD

SDGR

SMMT

SWKS

SYNA

TEVA

TSLA

ULTA

VKTX

VRSN

VRTX

VTRS

Press Releases

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium

Schrödinger to Announce Third Quarter 2024 Financial Results on November 12

Schrödinger to Present at Jefferies London Healthcare Conference

Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis

Schrödinger Reports Third Quarter 2024 Financial Results

Schrödinger Broadens and Accelerates Predictive Toxicology Initiative

Schrödinger to Present at Piper Sandler 36th Annual Healthcare Conference

MultiPlan Corporation Class A Common Stock

MultiPlan

OneMedNet

OptimizeRx

Phreesia

Pheton Holdings Ltd - Class A Ordinary Shares

Pheton Holdings

Scienture Holdings

Simulations Plus

Sophia Genetics

Streamline Health Solutions, Inc. - Common Stock

Streamline Health Solns

TruBridge

Teladoc Health

Veeva Systems

VSee Health

Waystar Holding

BMO Capital

Morgan Stanley

Keybanc

Leerink Partners

Citigroup

Comments

Schrodinger

Noticias

Últimas noticias sobre Schrodinger (NASDAQ:SDGR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL